Next Article in Journal
Cross-Sectional Study: Associations of A20 and Cezanne with Leukocyte Accumulation in B-Cell Acute Lymphoblastic Leukemia
Previous Article in Journal
High Rate of Inappropriate Utilization of an Ophthalmic Emergency Department: A Prospective Analysis of Patient Perceptions and Contributing Factors
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Association Between Perinasal Uptake on Radioactive Iodine Whole-Body Scan and Nasolacrimal Duct Obstruction

1
Department of Nuclear Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan 05505, Republic of Korea
2
Department of Nuclear Medicine, Dongnam Institution of Radiological & Medical Sciences (DIRAMS), Busan 46033, Republic of Korea
3
Department of Opthalmology, Ulsan University Hospital, Ulsan 44033, Republic of Korea
4
Namu Eye Clinic, Yongin-si 16841, Republic of Korea
*
Authors to whom correspondence should be addressed.
Minjung Seo and Hongje Lee contributed equally as first authors.
Medicina 2025, 61(7), 1165; https://doi.org/10.3390/medicina61071165
Submission received: 2 June 2025 / Revised: 23 June 2025 / Accepted: 26 June 2025 / Published: 27 June 2025
(This article belongs to the Section Surgery)

Abstract

Background and Objectives: This study reports an association between nasolacrimal duct obstruction (NLDO) and perinasal uptake on radioactive iodine (RAI) whole-body scan. Materials and Methods: This is a retrospective study of 37 patients from May to November 2017 who underwent thyroidectomy and I-131 ablation for papillary thyroid cancer (PTC) and had a follow-up I-123 diagnostic WBS and dacryoscintigraphy. Ophthalmic examinations assessed punctal stenosis, NLDO, tear film break-up time, Schirmer’s test, punctate keratopathy, tear meniscus height, epiphora, and ocular dryness. Perinasal and nasal uptake on whole-body scans (WBSs) were assessed as negative (no uptake) or positive (focal uptake). The associations between perinasal uptake on WBS, dacryoscintigraphy findings, and ophthalmic assessments were assessed. Results: Nasal uptake on I-131 post-ablation WBS were observed in 60 eyes (81%); perinasal uptake was observed in 8 eyes (11%). Nasal uptake on I-123 post-ablation WBS were observed in all eyes; perinasal uptake was observed in 15 eyes (20%). Perinasal and nasal uptake on I-131 post-ablation WBS were significantly associated with delayed excretion on dacryoscintigraphy (p < 0.001 and p = 0.03, respectively). Perinasal uptake on I-123 WBS was associated with both abnormal dacryoscintigraphy findings and ocular dryness (p < 0.001 and p = 0.02, respectively). Conclusions: Perinasal uptake on I-131 post-ablation and I-123 diagnostic WBS was significantly associated with delayed excretion on dacryoscintigraphy, suggesting NLDO.

1. Introduction

Radioactive iodine (RAI) therapy is widely used for remnant ablation or as adjuvant treatment in patients with differentiated thyroid cancer (DTC) following thyroidectomy [1]. It improves survival and reduces recurrence in these patients [2,3,4]. After administration, iodine-131 (I-131) is actively transported into thyroid follicular or tumor cells via the sodium–iodide symporter (NIS) [1,5]. However, the NIS is also expressed in various extrathyroidal tissues such as the salivary glands, gastric mucosa, breast, thymus, lacrimal gland, and nasolacrimal drainage system [6]. Unintended irradiation of these tissues during RAI therapy can cause side effects including nasolacrimal duct obstruction (NLDO) [7,8].
Although salivary and lacrimal gland dysfunctions after I-131 therapy are well documented, studies focusing specifically on NLDO are limited [9,10]. A significant proportion of ingested radioactive iodine is excreted in tears, potentially leading to the damage of the lacrimal gland and nasolacrimal duct [11,12]. NLDO is a well-established complication of I-131 therapy, with reported incidences ranging from 2% to 18%, particularly in patients over 45 years of age or those receiving cumulative doses above 100–150 mCi (3.7–5.55 GBq) [13,14,15]. The pathogenesis involves radiotoxic epithelial injury mediated by the NIS, leading to inflammation, fibrosis, and obstruction of the lacrimal drainage system [14,16]. Morphological studies confirm epithelial desquamation, mucous gland injury, and fibrosis [16]. The American Thyroid Association and other reports stress the importance of clinician awareness, patient counseling, and timely referral for dacryocystorhinostomy when indicated [1,7,17]. To date, no study has directly assessed whether the abnormal I-131 uptake on WBS reflects functional nasolacrimal duct obstruction as confirmed by dacryoscintigraphy.
Current clinical practice mainly relies on symptom-based monitoring. In this study, we aimed to determine whether perinasal RAI uptake on WBS is associated with the dysfunction of the lacrimal drainage system, which could serve as an early predictor of lacrimal excretory dysfunction, as confirmed by dacryoscintigraphy.

2. Methods

2.1. Study Subjects

This study retrospectively analyzed 37 thyroid cancer patients who underwent thyroidectomy and I-131 ablation at Ulsan University Hospital (UUH) between May and November 2017, and then underwent a follow-up I-123 diagnostic WBS, dacryoscintigraphy, and ophthalmic examinations. The institutional review board at UUH approved the retrospective use of clinical data for this study (IRB No. 2023-3-015).

2.2. Data Analysis

2.2.1. I-131 and I-123 Whole-Body Scans

Patients underwent post-ablation I-131 WBS on either the 2nd or 7th day following RAI administration. I-123 WBSs were performed at least 100 days post-therapy. Perinasal and nasal uptake on WBS was classified as either negative (no uptake) or positive (focal uptake). Two nuclear medicine physicians reached a consensus on scan interpretations.

2.2.2. Lacrimal Drainage System

A. Dacryoscintigraphy
Dacryoscintigraphy was performed in a seated position, while ensuring that the SPECT detector was positioned as close to the eye as possible. A single drop of technetium-99m pertechnetate (50–100 µCi/eye) was instilled in the outer canthus of each eye. Images were acquired using SPECT with a high-resolution collimator. Delayed tracer excretion through the nasolacrimal system on dacryoscintigraphy was considered abnormal. Two nuclear medicine specialists reached a final interpretation by consensus.
B. Ophthalmic Examination
An ophthalmologist assessed patients’ lacrimal drainage system function using various tests such as punctal stenosis, NLDO, tear film break-up time (BUT), Schirmer’s test, punctate keratopathy, tear meniscus height (TMH), epiphora, and ocular dryness. NLDO was graded from 0 to 3: 0, none; 1, (1–50% reflux); 2, (50–99% reflux); and 3, total obstruction. An abnormal BUT was defined as a duration of <10 s. An abnormal Schirmer’s test was defined as tear production of <10 mm in 5 min. TMH was graded as 1, low; 2, low-to-normal; 3, normal; and 4, increased.

2.3. Statistical Analysis

Fisher’s exact test or chi-square test was used to assess the concordance between perinasal uptake on WBS and findings from the dacryoscintigraphy or ophthalmic assessment. SPSS version 21 (IBM SPSS Statistics Software, Armonk, NY, USA) was used for statistical analysis, with p < 0.05 considered statistically significant.

3. Results

3.1. Patient Characteristics and Examination Results

In total, 74 eyes (10 male; mean age of 50 years.) were studied. The mean RAI dose was 75 mCi, with 62% of patients receiving more than 30 mCi. No significant demographic differences were observed between patients receiving low (≤30 mCi) and high (>30 mCi) RAI doses. On post-ablation I-131 WBS, ipsilateral perinasal uptake was observed in 11% of patients and nasal uptake in 81%. On I-123 diagnostic WBS, perinasal and nasal uptake rates were 20% and 100%, respectively. The RAI ablation dose was not significantly associated with perinasal or nasal uptake in WBS. Abnormal dacryoscintigraphy findings were observed in 32% of patients.
On ophthalmic examination, NLDO (16%), ocular dryness 41%, epiphora (15%), and punctal stenosis (12%) were present. The demographic characteristics and detailed study results are presented in Table 1.

3.2. Association Between WBS and Dacryoscintigraphy

Eyes with ipsilateral perinasal uptake on I-131 and I-123 WBSs exhibited abnormal dacryoscintigraphy findings in 8 out of 8 eyes and 11 out of 15 eyes, respectively. Nasal uptake on I-131 and I-123 WBSs showed abnormal dacryoscintigraphy results of 38% (23/60 eyes) and 32% (24/50 eyes), respectively. A statistically significant association was found between perinasal uptake on I-131 WBS and abnormal dacryoscintigraphy findings (p < 0.001). Nasal uptake also showed a statistically significant correlation with abnormal dacryoscintigraphy findings (p = 0.03).
Similarly, perinasal uptake on I-123 WBS was significantly associated with abnormal dacryoscintigraphy findings (p < 0.001). Nasal uptake was not statistically evaluated. No statistically significant association was found between perinasal uptake on I-131 WBS and ophthalmic examinations, and nasal uptake was also not statistically significant. However, perinasal uptake on I-123 WBS was significantly associated with ocular dryness (p = 0.02), whereas no significant associations were identified with other ophthalmic parameters. Nasal uptake on I-123 WBS was not significantly correlated with any ophthalmic examination findings. The associations between WBSs and abnormal lacrimal system findings, as evaluated using dacryoscintigraphy and ophthalmic examinations, are summarized in Table 2. A representative case of abnormal dacryoscintigraphy and WBS findings is shown in Figure 1. The patient exhibited bilateral perinasal uptake on both I-131 and I-123 WBSs, whereas nasal uptake was relatively minimal. Although the ophthalmic examination was unremarkable, dacryoscintigraphy showed a severe excretion delay.

4. Discussion

We show that perinasal uptake on I-131 and I-123 WBSs are significantly associated with abnormal dacryoscintigraphy findings. To our knowledge, this is the first study to examine the relationship between extrathyroidal uptake on RAI WBSs and dacryoscintigraphy. Several reports have suggested that nasolacrimal duct or nasal uptake is linked to lacrimal dysfunction [18,19], but none have confirmed this using dacryoscintigraphy, which is a minimally invasive imaging test widely used to evaluate the function of the lacrimal excretory system and to diagnose NLDO. Dacryoscintigraphy allows dynamic assessment of tear excretion and is more sensitive in detecting partial or early-stage obstructions than anatomical imaging or lacrimal irrigation [18].
Bakheet et al. showed that radioactivity in tears collected via Schirmer’s test peaked 1 h after the ingestion of 15 mCi of I-123 and remained detectable at 24 h [12]. In this study, I-131 and I-123 WBSs were obtained on the 7th day and 24 h post-ingestion, respectively. Under normal conditions, the lacrimal glands, tear film, and lacrimal excretory system are not seen on RAI WBSs due to their small size, low tear flow rate, and rapid turnover rate of the tear film. However, individuals who exhibited radioactivity in these regions likely had a higher concentration of RAI uptake in the lacrimal excretory system, with prolonged retention compared to those without uptake. Such patients may be at an increased risk of NLD toxicity, as suggested by the findings of this study.
This study examined the association between the RAI WBS findings and ophthalmic examination. Although prior studies have reported RAI-related dacryocystitis, epiphora, and tear production changes, no study has comprehensively assessed the lacrimal excretion system via ophthalmologic evaluation. Only perinasal uptake on I-123 WBS was significantly associated with ocular dryness, while no significant associations were found with other ophthalmic parameters. However, dacryoscintigraphy successfully identified lacrimal excretion abnormalities that ophthalmologic examinations did not detect. Although NLDO is a recognized complication of RAI therapy, clinical management typically remains symptom driven. Patients are advised to monitor for tearing or ocular symptoms, which often arise 6 to 12 months following treatment [14,15]. However, identifying early imaging markers could enhance risk stratification, personalize follow-up protocols, and improve patient education. Asymptomatic individuals exhibiting perinasal uptake on WBSs may benefit from further evaluation with dacryoscintigraphy to detect early or subclinical dysfunction. Extended follow-up periods would be helpful to confirm this hypothesis.
This study also evaluated both perinasal and nasal uptake on WBSs. Several studies reported nasal uptake and described nasolacrimal duct uptake on post-ablation WBS [19,20]; however, no study has systematically analyzed uptake at both sites using diagnostic WBSs. In this study, perinasal uptake on I-131 WBS exhibited a stronger association with abnormal dacryoscintigraphy findings than that on I-123 WBS. Nasal uptake was highly prevalent (81% on I-131 and 100% on I-123 WBSs). Based on these findings, perinasal uptake on RAI WBSs may serve as a useful predictor of lacrimal excretory system abnormalities. This study had several limitations, including its small size and lack of follow-up clinical and imaging data. Larger scale studies with longer follow-up durations would be helpful to confirm our study.

5. Conclusions

Perinasal uptake on I-131 post-ablation and I-123 diagnostic WBSs was significantly associated with delayed excretion on dacryoscintigraphy, suggestive of NLDO. Perinasal uptake may serve as a predictive marker of preclinical lacrimal excretory dysfunction and support the need for close surveillance and ophthalmological follow-up.

Author Contributions

Conceptualization, H.L. and J.-H.L.; methodology, M.S., H.L. and N.R.P.; software, M.S. and H.L.; validation, J.-H.L. and S.H.P.; formal analysis, M.S. and H.L.; investigation, H.L.; resources, N.R.P. and J.-H.L.; data curation, M.S. and N.R.P.; writing—original draft preparation, M.S. and H.L.; writing—review and editing, S.H.P.; visualization, M.S.; supervision, J.-H.L. and S.H.P.; project administration, J.-H.L. and S.H.P.; funding acquisition, none. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review of Ulsan University Hospital (No. 2023-03-015 and approved on 5 April 2023).

Informed Consent Statement

Patient consent was waived due to the retrospective nature of this study.

Data Availability Statement

No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Haugen, B.R.; Alexander, E.K.; Bible, K.C.; Doherty, G.M.; Mandel, S.J.; Nikiforov, Y.E.; Pacini, F.; Randolph, G.W.; Sawka, A.M.; Schlumberger, M.; et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016, 26, 1–133. [Google Scholar] [CrossRef]
  2. Mazzaferri, E.L.; Jhiang, S.M. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am. J. Med. 1994, 97, 418–428. [Google Scholar] [CrossRef] [PubMed]
  3. Mazzaferri, E.L.; Jhiang, S.M. Differentiated thyroid cancer long-term impact of initial therapy. Trans. Am. Clin. Climatol. Assoc. 1995, 106, 151–168, discussion 168–170. [Google Scholar] [PubMed]
  4. Mazzaferri, E.L. An overview of the management of papillary and follicular thyroid carcinoma. Thyroid 1999, 9, 421–427. [Google Scholar] [CrossRef] [PubMed]
  5. Chung, J.K.; Youn, H.W.; Kang, J.H.; Lee, H.Y.; Kang, K.W. Sodium iodide symporter and the radioiodine treatment of thyroid carcinoma. Nucl. Med. Mol. Imaging 2010, 44, 4–14. [Google Scholar] [CrossRef] [PubMed]
  6. Koca, G.; Singar, E.; Akbulut, A.; Yazihan, N.; Yumuşak, N.; Demir, A.; Korkmaz, M. The effect of resveratrol on radioiodine therapy-associated lacrimal gland damage. Curr. Eye Res. 2021, 46, 398–407. [Google Scholar] [CrossRef] [PubMed]
  7. Yartsev, V.D.; Solodkiy, V.A.; Fomin, D.K.; Borisenko, T.E.; Atkova, E.L. Clinical and demographic characteristics of tearing in patients after radioiodine ablation for differentiated thyroid cancer. Curr. Eye Res. 2021, 46, 1320–1324. [Google Scholar] [CrossRef] [PubMed]
  8. Solans, R.; Bosch, J.A.; Galofré, P.; Porta, F.; Roselló, J.; Selva-O’Callagan, A.; Vilardell, M. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. J. Nucl. Med. 2001, 42, 738–743. [Google Scholar] [PubMed]
  9. Sun, G.E.; Hatipoglu, B. Epiphora after radioactive iodine ablation for thyroid cancer. Thyroid 2013, 23, 243–245. [Google Scholar] [CrossRef] [PubMed]
  10. Rahmanipour, E.; Askari, E.; Ghorbani, M.; Mirzaei, M.; Rahimi, B.; Daskareh, M.; Mirshahvalad, S.A. Eye-related adverse events after I-131 radioiodine therapy: A systematic review of the current literature. Endocr. Pract. 2024, 30, 770–778. [Google Scholar] [CrossRef] [PubMed]
  11. Bakheet, S.M.; Hammami, M.M. False-positive radioiodine whole-body scan in thyroid cancer patients due to unrelated pathology. Clin. Nucl. Med. 1994, 19, 325–329. [Google Scholar] [CrossRef] [PubMed]
  12. Bakheet, S.M.; Hammami, M.M.; Hemidan, A.; Powe, J.E.; Bajaafar, F. Radioiodine secretion in tears. J. Nucl. Med. 1998, 39, 1452–1454. [Google Scholar] [PubMed]
  13. Al-Qahtani, K.H.; Al Asiri, M.; Tunio, M.A.; Aljohani, N.J.; Bayoumi, Y.; Munir, I.; AlAyoubi, A. Nasolacrimal duct obstruction following radioactive iodine-131 therapy in differentiated thyroid cancers: Review of 19 cases. Clin. Ophthalmol. 2014, 8, 2479–2484. [Google Scholar] [PubMed]
  14. Ali, M.J. Iodine-131 therapy and nasolacrimal duct obstructions: What we know and what we need to know. Ophthal. Plast. Reconstr. Surg. 2016, 32, 243–248. [Google Scholar] [CrossRef] [PubMed]
  15. Lee, I.T.; Chen, W.; Chen, Q.; Cole, H.A.; Bischoff, L.A.; Jessop, A.C.; Sobel, R.K. Factors associated with radioactive iodine therapy-acquired nasolacrimal duct obstruction. Endocr. Pract. 2022, 28, 1210–1215. [Google Scholar] [CrossRef] [PubMed]
  16. Fedorov, A.A.; Atkova, E.L.; Yartsev, V.D. Secondary acquired nasolacrimal duct obstruction as a specific complication of treatment with radioactive iodine (morphological study). Ophthal. Plast. Reconstr. Surg. 2020, 36, 250–253. [Google Scholar] [CrossRef] [PubMed]
  17. da Fonseca, F.L.; Yamanaka, P.K.; Kato, J.M.; Matayoshi, S. Lacrimal system obstruction after radioiodine therapy in differentiated thyroid carcinomas: A prospective comparative study. Thyroid 2016, 26, 1761–1767. [Google Scholar] [CrossRef] [PubMed]
  18. Fard-Esfahani, A.; Gholamrezanezhad, A.; Mirpour, S.; Tari, A.S.; Saghari, M.; Beiki, D.; Sichani, B.F.; Eftekhari, M. Assessment of the accuracy of lacrimal scintigraphy based on a prospective analysis of patients’ symptomatology. Orbit 2008, 27, 237–241. [Google Scholar] [CrossRef] [PubMed]
  19. Ali, M.J.; Vyakaranam, A.R.; Rao, J.E.; Prasad, G.; Reddy, P.V. Iodine-131 therapy and lacrimal drainage system toxicity: Nasal localization studies using whole body nuclear scintigraphy and SPECT-CT. Ophthal. Plast. Reconstr. Surg. 2017, 33, 13–16. [Google Scholar] [CrossRef] [PubMed]
  20. Sakahara, H.; Yamashita, S.; Suzuki, K.; Imai, M.; Kosugi, T. Visualization of nasolacrimal drainage system after radioiodine therapy in patients with thyroid cancer. Ann. Nucl. Med. 2007, 21, 525–527. [Google Scholar] [CrossRef] [PubMed]
Figure 1. A patient who underwent radioactive iodine ablation exhibited a severe excretion delay on early (A) and late (B) images of dacryoscintigraphy. Although nasal uptake was relatively minimal, bilateral perinasal uptakes (arrows) were observed on both I-131 (C) and I-123 whole-body scans (D). Remnant thyroid uptake was also noted on I-131 whole-body scan.
Figure 1. A patient who underwent radioactive iodine ablation exhibited a severe excretion delay on early (A) and late (B) images of dacryoscintigraphy. Although nasal uptake was relatively minimal, bilateral perinasal uptakes (arrows) were observed on both I-131 (C) and I-123 whole-body scans (D). Remnant thyroid uptake was also noted on I-131 whole-body scan.
Medicina 61 01165 g001
Table 1. Patient characteristics, radioactive iodine whole-body scan findings, dacryoscintigraphy results, and ophthalmic examination outcomes in 37 patients (74 eyes).
Table 1. Patient characteristics, radioactive iodine whole-body scan findings, dacryoscintigraphy results, and ophthalmic examination outcomes in 37 patients (74 eyes).
VariableResults
Sex, n
  Men10
  Women27
Mean age, years (range)50 (22–74)
Mean RAI dose, mCi (range)75 (30–150)
Abnormal RAI WBS uptakes
  Perinasal uptake (+), % (eyes)
     I-131 WBS11 (8)
     I-123 WBS20 (15)
  Nasal uptake (+), % (eyes)
     I-131 WBS8 (60)
     I-123 WBS100 (74)
Abnormal dacryoscintigraphy, % (eyes) 32 (24)
Abnormal ophthalmic examination, % (eyes)
  Nasolacrimal duct obstruction16 (12)
  Ocular dryness41 (30)
  Epiphora15 (11)
  Punctal stenosis12 (9)
  Tear film break-up time96 (71) *
  Schirmer’s test25 (18/72)
  Punctate keratopathy 51 (38)
  Tear meniscus height 35 (26)
n, number; RAI, radioactive iodine; WBS, whole-body scan. * Schirmer’s test was not performed in one patient (two eyes). Tear film break-up time was not performed in one patient (two eyes).
Table 2. Association between radioactive iodine whole-body scan findings and lacrimal duct system assessments.
Table 2. Association between radioactive iodine whole-body scan findings and lacrimal duct system assessments.
VariableI-131 WBSI-123 WBS
Perinasal UptakeNasal Uptake Perinasal UptakeNasal Uptake
NoYesp *NoYesp *NoYesp *NoYesp *
Dacryoscintigraphy <0.001 0.03 <0.001 NA
 Normal500 1337 464 050
 Abnormal168 123 1311 024
Punctal stenosis 0.58 0.36 1.0 NA
 No578 1154 5213 065
 Yes90 36 73 09
NLDO 1.0 0.44 0.44 NA
 No557 1349 4814 062
 Yes111 111 111 012
Epiphora 1.0 0.11 0.22 NA
 No567 1449 5211 063
 Yes101 011 74 011
Dryness 0.13 0.16 0.02 NA
 No377 638 3113 044
 Yes291 822 282 030
Tear film break-up time 1.0 0.18 1.0 NA
 Normal71 35 71 05
 Abnormal577 1153 5014 064
Schirmer’s test 0.67 0.74 0.1 NA
 Normal171 414 171 018
 Abnormal477 1044 4014 054
Punctate keratopathy 0.15 0.91 0.68 NA
 Normal306 729 288 036
 Abnormal362 731 317 038
Tear meniscus height 1.0 1.0 1.0 NA
 Normal658 1459 5815 073
 Abnormal10 01 10 01
WBS, whole-body scan; NA, not assessable; NLDO, nasolacrimal duct obstruction (assessed by an ophthalmologist). * Chi-square or Fisher’s Exact Test.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Seo, M.; Lee, H.; Park, N.R.; Lee, J.-H.; Park, S.H. Association Between Perinasal Uptake on Radioactive Iodine Whole-Body Scan and Nasolacrimal Duct Obstruction. Medicina 2025, 61, 1165. https://doi.org/10.3390/medicina61071165

AMA Style

Seo M, Lee H, Park NR, Lee J-H, Park SH. Association Between Perinasal Uptake on Radioactive Iodine Whole-Body Scan and Nasolacrimal Duct Obstruction. Medicina. 2025; 61(7):1165. https://doi.org/10.3390/medicina61071165

Chicago/Turabian Style

Seo, Minjung, Hongje Lee, Na Ri Park, Ju-Hyang Lee, and Seol Hoon Park. 2025. "Association Between Perinasal Uptake on Radioactive Iodine Whole-Body Scan and Nasolacrimal Duct Obstruction" Medicina 61, no. 7: 1165. https://doi.org/10.3390/medicina61071165

APA Style

Seo, M., Lee, H., Park, N. R., Lee, J.-H., & Park, S. H. (2025). Association Between Perinasal Uptake on Radioactive Iodine Whole-Body Scan and Nasolacrimal Duct Obstruction. Medicina, 61(7), 1165. https://doi.org/10.3390/medicina61071165

Article Metrics

Back to TopTop